Why the study?
Do aminopeptidases (P-LAP and APA) reduce blood pressure and prolong gestation in preclinical models of preeclampsia and preterm labor?
Do aminopeptidases (P-LAP and APA) reduce blood pressure and prolong gestation in preclinical models of preeclampsia and preterm labor?
Aminopeptidases such as P-LAP and APA represent potential novel therapeutic targets for safely treating preeclampsia and preterm labor without crossing the placental barrier.
Answers are grounded in this paper and cite their sources.
Supports aminopeptidase targets in preeclampsia models; leaves open human translation and safety before any practice consideration.
Preeclampsia and preterm delivery are important potential complications in pregnancy and represent the leading causes for maternal and perinatal morbidity and mortality. The mechanisms underlying both diseases remain unknown, thus available treatments (beta2-stimulants and magnesium sulfate) are essentially symptomatic. Both molecules have molecular weights less than 5-8 kDa, cross the placental barrier, and thus exert their effects on the fetus. The fetus produces peptides that are highly vasoactive and uterotonic and increase in response to maternal stress and with continued development. Fetal peptides are also small molecules that inevitably leak across into the maternal circulation. Aminopeptidases such as placental leucine aminopeptidase (P-LAP) and aminopeptidase A (APA) are large molecules that do not cross the placental barrier. We have shown that APA acts as an antihypertensive agent in the pregnant spontaneously hypertensive rat by degrading vasoactive peptides and as a result returns the animal to a normotensive state. P-LAP also acts as an antiuterotonic agent by degrading uterotonic peptides and thus prolongs gestation in the pregnant mouse. Given the ever increasing worldwide incidences of preeclampsia and preterm labor, it is imperative that new agents be developed to safely prolong gestation. We believe that the use of aminopeptidases hold promise in this regard.
No takes yet. Share an insight, caveat, or question.
Mizutani et al. (2010) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: